Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
60 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-04-19
Study Completion Date
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Eosinophilic esophagitis is a recent and emerging chronic disease, secondary to eosinophilic infiltration of the esophageal mucosa leading to esophageal dysfunction. The diagnosis of this pathology, and monitoring of the efficacy of therapies, relies on the assessment of eosinophilic density on esophageal biopsies: follow-up requires numerous digestive endoscopies under general anesthesia, at each therapeutic change, to assess remission. The search for non-invasive biomarkers of active eosinophilic esophagitis is therefore a subject of major interest.
The first step is to study EDN (Eosinophil-Derived Neurotoxin), a protein secreted when eosinophils are activated. Several studies have investigated the association between serum EDN, EDN on esophageal brushing or esophageal biopsies with eosinophilic esophagitis activity, and the results look promising. Urinary EDN is associated with atopy but has not been studied in eosinophilic esophagitis. EDN is a biomarker of interest because it is stable over time and, above all, can be measured routinely, making it applicable to routine patient management and care. Our main objective is to evaluate the correlation of EDN in urine, blood and esophageal brushings with the eosinophilic infiltrate counted on esophageal biopsies in patients undergoing upper GI endoscopy at Trousseau Hospital for suspected eosinophilic esophagitis, or as part of the re-evaluation of known eosinophilic esophagitis under treatment.
Finally, esophageal and salivary dysbiosis has been described in eosinophilic esophagitis without direct evidence of its influence on esophageal inflammation and disease. Our secondary objective is to study the esophageal, salivary and fecal microbiota in these same patients in order to describe the composition, alpha and beta-diversity of bacterial and mycological flora between patients and controls, as well as their association with pathology, and to propose possible alternative therapies aimed at modulating the esophageal and/or salivary microbiota in the management of eosinophilic esophagitis.
This study will be carried out on a cohort of pediatric patients followed up in the pediatric nutrition and gastroenterology department of the Trousseau-APHP hospital and hospitalized for upper GI endoscopy, either as part of a suspected case of eosinophilic esophagitis, or during follow-up of a previously known case of eosinophilic esophagitis. Blood, urine, stool, saliva, 4 additional esophageal biopsies and esophageal brushings were collected on the day of the digestive endoscopy. Depending on the eosinophilic densitý on the biopsies, subjects will be classified into either the "patient with active eosinophilic esophagitis" group, the "patient with eosinophilic esophagitis in remission" group, or the "control without eosinophilic esophagitis" group. The investigator aim to include 60 patients undergoing upper GI endoscopy, at least half of whoḿ will have active or remitting eosinophilic esophagitis.
Furthermore, the study of the immunological, allergological and metabolomic signature of this disease is essential to enable the identification of new biomarkers to guide the creation of models combining several biomarkers predictive of eosinophilic density on esophageal biopsies. In a second step, the concentration of a panel of cytokines in blood and esophageal biopsies, the allergic sensitization profile in blood and esophageal biopsies, and an untargeted description of esophageal metabolomics will be compared between groups. In terms of clinical prospects, the investigator plan to develop a patient follow-up strategy based on the biomarkers studied, which is better adapted to clinical practice, better tolerated by patients and less costly than repeated endoscopies with esophageal biopsies.
The first step is to study EDN (Eosinophil-Derived Neurotoxin), a protein secreted when eosinophils are activated. Several studies have investigated the association between serum EDN, EDN on esophageal brushing or esophageal biopsies with eosinophilic esophagitis activity, and the results look promising. Urinary EDN is associated with atopy but has not been studied in eosinophilic esophagitis. EDN is a biomarker of interest because it is stable over time and, above all, can be measured routinely, making it applicable to routine patient management and care. Our main objective is to evaluate the correlation of EDN in urine, blood and esophageal brushings with the eosinophilic infiltrate counted on esophageal biopsies in patients undergoing upper GI endoscopy at Trousseau Hospital for suspected eosinophilic esophagitis, or as part of the re-evaluation of known eosinophilic esophagitis under treatment.
Finally, esophageal and salivary dysbiosis has been described in eosinophilic esophagitis without direct evidence of its influence on esophageal inflammation and disease. Our secondary objective is to study the esophageal, salivary and fecal microbiota in these same patients in order to describe the composition, alpha and beta-diversity of bacterial and mycological flora between patients and controls, as well as their association with pathology, and to propose possible alternative therapies aimed at modulating the esophageal and/or salivary microbiota in the management of eosinophilic esophagitis.
This study will be carried out on a cohort of pediatric patients followed up in the pediatric nutrition and gastroenterology department of the Trousseau-APHP hospital and hospitalized for upper GI endoscopy, either as part of a suspected case of eosinophilic esophagitis, or during follow-up of a previously known case of eosinophilic esophagitis. Blood, urine, stool, saliva, 4 additional esophageal biopsies and esophageal brushings were collected on the day of the digestive endoscopy. Depending on the eosinophilic densitý on the biopsies, subjects will be classified into either the "patient with active eosinophilic esophagitis" group, the "patient with eosinophilic esophagitis in remission" group, or the "control without eosinophilic esophagitis" group. The investigator aim to include 60 patients undergoing upper GI endoscopy, at least half of whoḿ will have active or remitting eosinophilic esophagitis.
Furthermore, the study of the immunological, allergological and metabolomic signature of this disease is essential to enable the identification of new biomarkers to guide the creation of models combining several biomarkers predictive of eosinophilic density on esophageal biopsies. In a second step, the concentration of a panel of cytokines in blood and esophageal biopsies, the allergic sensitization profile in blood and esophageal biopsies, and an untargeted description of esophageal metabolomics will be compared between groups. In terms of clinical prospects, the investigator plan to develop a patient follow-up strategy based on the biomarkers studied, which is better adapted to clinical practice, better tolerated by patients and less costly than repeated endoscopies with esophageal biopsies.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Outcome of Children With Eosinophilic Esophagitis
NCT06190080
Esophagitis, Eosinophilic
NOT_YET_RECRUITING
NA
Inflammatory Mediators as Potential Non-Invasive Biomarkers in Subjects With Eosinophilic Esophagitis
NCT03822325
Eosinophilic Esophagitis
ACTIVE_NOT_RECRUITING
Phenotypic Characterization and Biomarkers Investigation for Eosinophilic Esophagitis in Pediatric Patients
NCT03069573
Eosinophilic Esophagitis
Gastroesophageal Reflux
COMPLETED
Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index
NCT00939263
Deglutition Disorders
Esophageal Diseases
Eosinophilia
UNKNOWN
Local Clinical and Immunological Responses in Eosinophilic Esophagitis (EoE) Patients, Role of Mucosal Barrier Function and Type II Inflammation
NCT07012928
Eosinophilic Esophagitis (EoE)
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Eosinophilic esophagitis is a chronic, inflammatory digestive disease of immunological and allergic origin, secondary to eosinophilic infiltration of the esophageal mucosa leading to esophageal dysfunction. It is an emerging disease whose incidence has been rising in pediatrics over recent decades, with an estimated annual incidence of 3 to 12 / 100,000 and a prevalence between 22 and 49 / 100,000. It is the second most common cause of chronic esophagitis, after peptic esophagitis.
There are chronic symptoms (severe reflux, dysphagia, sensation of food blockage and need to drink water during meals to swallow), or sometimes acutely (e.g. sudden food impaction during a meal, with hypersialorrhea), requiring emergency endoscopy. It can be complicated by esophageal fibrosis, stenosis, or esophageal perforation.
The diagnosis of eosinophilic esophagitis is histological, based on the demonstration of \> 15 eosinophils/field (magnification x 400) on at least one esophageal biopsy. Several therapies have been tried and tested over the years: proton pump inhibitors (PPIs), eviction diets, local corticosteroid therapy and, more recently, immunotherapies. To confirm remission of the disease or justify changes in treatment, endoscopic re-evaluation is regularly required (every 8 to 12 weeks after the introduction of a new treatment, then annually during maintenance treatment or earlier in the event of clinical relapse). Patient follow-up therefore requires numerous digestive endoscopies, mostly performed under general anesthesia in pediatrics, an invasive procedure with a potential risk of complications.
The identification of non-invasive biomarkers of active eosinophilic esophagitis would enable us to propose a diagnostic and follow-up strategy better adapted to clinical practice and better tolerated by patients.
EDN, Eosinophil-Derived Neurotoxin, is a protein secreted when eosinophils are activated. Serum EDN has been extensively studied in atopy. In eosinophilic esophagitis, it appears to correlate significantly with the densitý of eosinophils on esophageal biopsies and would therefore be higher in patients with active eosinophilic esophagitis than in controls. Some teams have even proposed cut-off values for blood EDN using ROC curves to optimize the sensitivitý and specificitý of this marker for the diagnosis of eosinophilic esophagitis in pediatrics. Serum EDN appears to decrease significantly in patients under treatment.
Other studies have focused́ on EDN on esophageal biopsies. A 2010 study assessed the distribution of intra- and extracellular EDN deposits on esophageal biopsies from patients followed up for eosinophilic esophagitis and in controls, using an immunofluorescence technique. EDN staining was clearly observed in biopsies from all patients, and absent or very weak in control subjects. However, conclusions concerning the correlation between tissue EDN and eosinophilic infiltration density differ.
The most recent data concern esophageal brush EDN, performed directly during digestive endoscopy or indirectly via a weighted oro-esophageal system. Luminal EDN was significantly higher in patients with active eosinophilic esophagitis than in patients with eosinophilic esophagitis in remission, gastroesophageal reflux disease or controls. It is even predictive of response to PPI therapy. EDN and other endoluminal markers were predictive of disease activity, including the development of secondary fibrosis and other complications.
Urinary EDN has been analyzed in atopic diseases, notably asthma and atopic dermatitis. It appears to be associated with eosinophil activity in these allergic diseases. There are no studies of urinary EDN in eosinophilic esophagitis.
To date, no studies have been carried out on the correlation between the different EDN assays.
EDN seems promising, but the identification of other biomarkers correlated with eosinophilic esophagitis activity is an additional challenge to enable the creation of models combining several biomarkers predictive of eosinophilic density on esophageal biopsies. To this end, more precise knowledge of the immunologic, allergologic and metabolomic signature of this disease seems invaluable. A study published in 2023 carried out an analysis of immune system activation from esophageal biopsies and blood samples, as well as an untargeted metabolomics analysis from blood samples. The results of this study suggest that a plasma signature specific to eosinophilic esophagitis could be identified from metabolomic data and cytokine information.
Finally, microbiota have been implicated in the pathogenesis of several digestive and extra-digestive allergic and inflammatory diseases, such as asthma and eczema. Only four studies have recently explored the role of esophageal, salivary and fecal microbiota in patients with eosinophilic esophagitis. Dysbiosis has been described, with an increased esophageal microbial load and a particular abundance of certain species (Haemophilus, Streptococcus) compared to control subjects, lower salivary bacterial diversity, and a similar fecal microbiota in patients and controls. Nevertheless, there is little direct evidence to demonstrate the influence of esophageal and/or salivary microbiota on inflammation and disease.
The investigator hypothesize that a peripheral signature of the disease correlates with the esophageal eosinophilic infiltrate. The investigator believe that not only urinary, serum and endoluminal EDN concentrations, but also serum and esophageal cytokine profiles and esophageal metabolomics correlate with eosinophilic infiltration on esophageal biopsies, and thus correlate with disease activity in patients with active eosinophilic esophagitis. In patients with eosinophilic esophagitis in remission and in controls, the investigator expect to observe normal or low EDN values and a different cytokine profile compared with patients with active eosinophilic esophagitis. The investigator also expect to observe esophageal and salivary dysbiosis in patients with active eosinophilic esophagitis.
In terms of clinical prospects, the investigator hope that these results will enable the development of non-invasive biomarker panels predictive of disease activity, and thus limit the number of digestive endoscopies required to monitor patients.
The study will be carried out on a cohort of pediatric patients followed in the pediatric nutrition and gastroenterology department of the Trousseau-APHP hospital and hospitalized for upper GI endoscopy, either as part of a suspected case of eosinophilic esophagitis, or during follow-up of a previously known case of eosinophilic esophagitis. Written consent will be obtained from parents, and from children according to their level of understanding.
Blood sample on the catheter required for general anesthesia, an unstimulated saliva collection, per-endoscopic esophageal brushing and 4 additional esophageal biopsies will be taken during digestive endoscopy. A urine sample and a stool sample will also be collected during hospitalization for digestive endoscopy.
Depending on the histological results and the eosinophilic densitý on the biopsies, which corresponds to the gold standard for making the diagnosis and assessing the activity of eosinophilic esophagitis, subjects will be classified either in the "patient with active eosinophilic esophagitis" group, the "patient with eosinophilic esophagitis in remission" group, or the "patient without eosinophilic esophagitis" group, which will correspond to a comparator control group. This group will therefore be defined a posteriori.
Urinary, serum and endoluminal esophageal brushing EDN values will be measured by ELISA or qPCR at INRAe or Pitié-Salpêtrière. Total and specific IgE, Phadiatop®, tryptase, CBC and eosinophil activation tests will be performed at the Groupe Hospitalier de l'Est Parisien biochemistry-allergology laboratory. If the Phadiatop® test is positive, additional tests will be carried out on the blood already collected to determine the level of pneumoallergen-specific IgE. Analysis of cytokine profiles on blood samples and esophageal biopsies, as well as non-targeted metabolomic analyses, will be carried out at INRAe in a second phase, once all samples have been taken.
In addition, extractions of salivary, esophageal and fecal bacterial and fungal DNA will be performed at INRAe, and sequencing at the @Bridge platform.
On the day of the digestive endoscopy, children and/or their parents will complete the PedsQL® and PEESS questionnaires.
Our main objective is to evaluate the correlation of EDN in urine, blood and esophageal brushings with the eosinophilic infiltrate counted on esophageal biopsies. Then, the concentration of a panel of cytokines in blood and esophageal biopsies, the allergic sensitization profile in blood and esophageal biopsies, and an untargeted description of esophageal metabolomics will be compared between groups.
Our secondary objective is to study the esophageal, salivary and fecal microbiota in these same patients in order to describe the composition, alpha and beta-diversity of bacterial and mycological flora between patients and controls, as well as their association with pathology, and to propose possible alternative therapies aimed at modulating the esophageal and/or salivary microbiota in the management of eosinophilic esophagitis. Primary and secondary outcomes are detailed below.
There are chronic symptoms (severe reflux, dysphagia, sensation of food blockage and need to drink water during meals to swallow), or sometimes acutely (e.g. sudden food impaction during a meal, with hypersialorrhea), requiring emergency endoscopy. It can be complicated by esophageal fibrosis, stenosis, or esophageal perforation.
The diagnosis of eosinophilic esophagitis is histological, based on the demonstration of \> 15 eosinophils/field (magnification x 400) on at least one esophageal biopsy. Several therapies have been tried and tested over the years: proton pump inhibitors (PPIs), eviction diets, local corticosteroid therapy and, more recently, immunotherapies. To confirm remission of the disease or justify changes in treatment, endoscopic re-evaluation is regularly required (every 8 to 12 weeks after the introduction of a new treatment, then annually during maintenance treatment or earlier in the event of clinical relapse). Patient follow-up therefore requires numerous digestive endoscopies, mostly performed under general anesthesia in pediatrics, an invasive procedure with a potential risk of complications.
The identification of non-invasive biomarkers of active eosinophilic esophagitis would enable us to propose a diagnostic and follow-up strategy better adapted to clinical practice and better tolerated by patients.
EDN, Eosinophil-Derived Neurotoxin, is a protein secreted when eosinophils are activated. Serum EDN has been extensively studied in atopy. In eosinophilic esophagitis, it appears to correlate significantly with the densitý of eosinophils on esophageal biopsies and would therefore be higher in patients with active eosinophilic esophagitis than in controls. Some teams have even proposed cut-off values for blood EDN using ROC curves to optimize the sensitivitý and specificitý of this marker for the diagnosis of eosinophilic esophagitis in pediatrics. Serum EDN appears to decrease significantly in patients under treatment.
Other studies have focused́ on EDN on esophageal biopsies. A 2010 study assessed the distribution of intra- and extracellular EDN deposits on esophageal biopsies from patients followed up for eosinophilic esophagitis and in controls, using an immunofluorescence technique. EDN staining was clearly observed in biopsies from all patients, and absent or very weak in control subjects. However, conclusions concerning the correlation between tissue EDN and eosinophilic infiltration density differ.
The most recent data concern esophageal brush EDN, performed directly during digestive endoscopy or indirectly via a weighted oro-esophageal system. Luminal EDN was significantly higher in patients with active eosinophilic esophagitis than in patients with eosinophilic esophagitis in remission, gastroesophageal reflux disease or controls. It is even predictive of response to PPI therapy. EDN and other endoluminal markers were predictive of disease activity, including the development of secondary fibrosis and other complications.
Urinary EDN has been analyzed in atopic diseases, notably asthma and atopic dermatitis. It appears to be associated with eosinophil activity in these allergic diseases. There are no studies of urinary EDN in eosinophilic esophagitis.
To date, no studies have been carried out on the correlation between the different EDN assays.
EDN seems promising, but the identification of other biomarkers correlated with eosinophilic esophagitis activity is an additional challenge to enable the creation of models combining several biomarkers predictive of eosinophilic density on esophageal biopsies. To this end, more precise knowledge of the immunologic, allergologic and metabolomic signature of this disease seems invaluable. A study published in 2023 carried out an analysis of immune system activation from esophageal biopsies and blood samples, as well as an untargeted metabolomics analysis from blood samples. The results of this study suggest that a plasma signature specific to eosinophilic esophagitis could be identified from metabolomic data and cytokine information.
Finally, microbiota have been implicated in the pathogenesis of several digestive and extra-digestive allergic and inflammatory diseases, such as asthma and eczema. Only four studies have recently explored the role of esophageal, salivary and fecal microbiota in patients with eosinophilic esophagitis. Dysbiosis has been described, with an increased esophageal microbial load and a particular abundance of certain species (Haemophilus, Streptococcus) compared to control subjects, lower salivary bacterial diversity, and a similar fecal microbiota in patients and controls. Nevertheless, there is little direct evidence to demonstrate the influence of esophageal and/or salivary microbiota on inflammation and disease.
The investigator hypothesize that a peripheral signature of the disease correlates with the esophageal eosinophilic infiltrate. The investigator believe that not only urinary, serum and endoluminal EDN concentrations, but also serum and esophageal cytokine profiles and esophageal metabolomics correlate with eosinophilic infiltration on esophageal biopsies, and thus correlate with disease activity in patients with active eosinophilic esophagitis. In patients with eosinophilic esophagitis in remission and in controls, the investigator expect to observe normal or low EDN values and a different cytokine profile compared with patients with active eosinophilic esophagitis. The investigator also expect to observe esophageal and salivary dysbiosis in patients with active eosinophilic esophagitis.
In terms of clinical prospects, the investigator hope that these results will enable the development of non-invasive biomarker panels predictive of disease activity, and thus limit the number of digestive endoscopies required to monitor patients.
The study will be carried out on a cohort of pediatric patients followed in the pediatric nutrition and gastroenterology department of the Trousseau-APHP hospital and hospitalized for upper GI endoscopy, either as part of a suspected case of eosinophilic esophagitis, or during follow-up of a previously known case of eosinophilic esophagitis. Written consent will be obtained from parents, and from children according to their level of understanding.
Blood sample on the catheter required for general anesthesia, an unstimulated saliva collection, per-endoscopic esophageal brushing and 4 additional esophageal biopsies will be taken during digestive endoscopy. A urine sample and a stool sample will also be collected during hospitalization for digestive endoscopy.
Depending on the histological results and the eosinophilic densitý on the biopsies, which corresponds to the gold standard for making the diagnosis and assessing the activity of eosinophilic esophagitis, subjects will be classified either in the "patient with active eosinophilic esophagitis" group, the "patient with eosinophilic esophagitis in remission" group, or the "patient without eosinophilic esophagitis" group, which will correspond to a comparator control group. This group will therefore be defined a posteriori.
Urinary, serum and endoluminal esophageal brushing EDN values will be measured by ELISA or qPCR at INRAe or Pitié-Salpêtrière. Total and specific IgE, Phadiatop®, tryptase, CBC and eosinophil activation tests will be performed at the Groupe Hospitalier de l'Est Parisien biochemistry-allergology laboratory. If the Phadiatop® test is positive, additional tests will be carried out on the blood already collected to determine the level of pneumoallergen-specific IgE. Analysis of cytokine profiles on blood samples and esophageal biopsies, as well as non-targeted metabolomic analyses, will be carried out at INRAe in a second phase, once all samples have been taken.
In addition, extractions of salivary, esophageal and fecal bacterial and fungal DNA will be performed at INRAe, and sequencing at the @Bridge platform.
On the day of the digestive endoscopy, children and/or their parents will complete the PedsQL® and PEESS questionnaires.
Our main objective is to evaluate the correlation of EDN in urine, blood and esophageal brushings with the eosinophilic infiltrate counted on esophageal biopsies. Then, the concentration of a panel of cytokines in blood and esophageal biopsies, the allergic sensitization profile in blood and esophageal biopsies, and an untargeted description of esophageal metabolomics will be compared between groups.
Our secondary objective is to study the esophageal, salivary and fecal microbiota in these same patients in order to describe the composition, alpha and beta-diversity of bacterial and mycological flora between patients and controls, as well as their association with pathology, and to propose possible alternative therapies aimed at modulating the esophageal and/or salivary microbiota in the management of eosinophilic esophagitis. Primary and secondary outcomes are detailed below.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Eosinophilic Esophagitis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
DIAGNOSTIC
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient with suspicion of eosinophilic esophagitis
Patients will benefit from blood, urine and stool sampling, esophageal brushing, and additional esophageal biopsies.
Group Type
EXPERIMENTAL
Blood sampling
Intervention Type
BIOLOGICAL
3 tubes of blood for research purposes (maximum 9.6 mL for children weighing 5-12 kg, 16 mL between 12-20 kg, 24 mL between 20 and 30 kg, and 56 mL for those weighing over 30 kg) will be taken from the catheter necessary for general anaesthesia.
Esophageal biopsies
Intervention Type
BIOLOGICAL
4 additional esophageal biopsies will be taken during digestive endoscopy, in the pathological zone or in the lower third of the esophagus by default.
Unstimulated saliva sampling
Intervention Type
BIOLOGICAL
A esophageal brushing will be done during digestive endoscopy.
Urine sampling
Intervention Type
BIOLOGICAL
A urine sample will be collected during hospitalization for digestive endoscopy.
Stool sampling
Intervention Type
BIOLOGICAL
A stool sample will be collected during hospitalization for digestive endoscopy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sampling
3 tubes of blood for research purposes (maximum 9.6 mL for children weighing 5-12 kg, 16 mL between 12-20 kg, 24 mL between 20 and 30 kg, and 56 mL for those weighing over 30 kg) will be taken from the catheter necessary for general anaesthesia.
Intervention Type
BIOLOGICAL
Esophageal biopsies
4 additional esophageal biopsies will be taken during digestive endoscopy, in the pathological zone or in the lower third of the esophagus by default.
Intervention Type
BIOLOGICAL
Unstimulated saliva sampling
A esophageal brushing will be done during digestive endoscopy.
Intervention Type
BIOLOGICAL
Urine sampling
A urine sample will be collected during hospitalization for digestive endoscopy.
Intervention Type
BIOLOGICAL
Stool sampling
A stool sample will be collected during hospitalization for digestive endoscopy.
Intervention Type
BIOLOGICAL
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Blood test/Blood collection
Biopsies of the esophagus
Unstimulated saliva collection
Urine collection
Stool collection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Suspicion of eosinophilic esophagitis due to symptoms of esophageal dysfunction OR follow-up of eosinophilic esophagitis histologically proven at a previous upper GI endoscopy.
* Indication for upper GI endoscopy for diagnosis or follow-up of eosinophilic esophagitis, or for pathology other than eosinophilic esophagitis.
* Indication for upper GI endoscopy for diagnosis or follow-up of eosinophilic esophagitis, or for pathology other than eosinophilic esophagitis.
Exclusion Criteria
\- Patients with chronic inflammatory bowel disease, esophageal atresia or achalasia
Minimum Eligible Age
2 Years
Maximum Eligible Age
17 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
INRAe - Micalis Institute - Jouy en Josas
UNKNOWN
Sponsor Role
collaborator
Assistance Publique - Hôpitaux de Paris
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anaïs LEMOINE, Doctor
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nutrition et gastro-entérologie pédiatrique-Trousseau Hospital
Paris, , France
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
France
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP231662
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Risk Factors and Biomarkers for Diagnosis and Treatment of EoE
NCT01988285
ACTIVE_NOT_RECRUITING
Swallowing Characteristics of Pediatric Patients With Eosinophilic Esophagitis
NCT04704752
COMPLETED
Non-endoscopic Tracking of Disease Activity in Eosinophilic Esophagitis
NCT03834298
WITHDRAWN
NA
Prevalence of Food Allergies in a Cohort of Adult Patients With Eosinophilic Esophagitis
NCT01631591
COMPLETED
Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis
NCT01479231
WITHDRAWN
PHASE1/PHASE2
Prevalence and Description of FIRE (Food Induced Immediate Response of the Esophagus) in the Pediatric Population With Eosinophilic Esophagitis
NCT06972147
RECRUITING
Use of Esophageal String Test to Understand Symptoms, Inflammation, and Function in Eosinophilic Esophagitis
NCT03305653
COMPLETED
NA
CEGIR 7808: Use of Unsedated Transnasal Esophagoscopy (TNE) to Monitor Dietary Management of Eosinophilic Esophagitis in Children
NCT03342391
COMPLETED
NA
The Potential Role of Compounds Derived From Ultra-processed Foods in Pathogenesis of Eosinophilic Esophagitis
NCT06093204
RECRUITING
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
NCT00728481
COMPLETED
PHASE2/PHASE3
Metabolomic Profiling of Eosinophilic Esophagitis
NCT03803527
WITHDRAWN
NA
The Effect of Sucralfate Slurry in Patients With Eosinophilic Esophagitis
NCT02353078
COMPLETED
EARLY_PHASE1
Metabolomics for Biomarker Discovery in Children With EoE
NCT03107819
COMPLETED
Prospective Multicenter Nationwide Registry of Children With Eosinophilic Esophagitis
NCT03858426
UNKNOWN
SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study
NCT02778867
COMPLETED
PHASE2/PHASE3
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
NCT06665971
RECRUITING
PHASE4
Eosinophilic Esophagitis: Influence of Dilation on Dysphagia and Inflammation
NCT00667524
COMPLETED
Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
NCT01022970
COMPLETED
PHASE2
Prospective Database for Eosinophilic Esophagitis (EoE) of Pediatric Population
NCT05176249
ACTIVE_NOT_RECRUITING
Monocentric Retrospective Observational Study for Validation of Meta-analysis of the Metatrascryptome and Transcriptome of Eosynophyl Esophagitis
NCT06071585
UNKNOWN
Esophageal String Test in Eosinophilic Esophagitis
NCT02008903
ACTIVE_NOT_RECRUITING
Eosinophilic Esophagitis: Towards Improved Management
NCT06991881
RECRUITING
Mucosal Impedance Balloon in Diagnosis and Treatment of Eosinophilic Esophagitis (EoE)
NCT02995395
COMPLETED
Allergy Immunotherapy in the Management of Eosinophilic Esophagitis
NCT01685034
WITHDRAWN
NA
Eating With Eosinophilic Esophagitis (EoE)
NCT03581838
COMPLETED